Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Vertex Pharmaceuticals initiated with an Overweight at Wells Fargo » 16:25
12/08/21
12/08
16:25
12/08/21
16:25
VRTX

Vertex Pharmaceuticals

$206.61 /

+1.28 (+0.62%)

, ABBV

AbbVie

$121.88 /

+0.395 (+0.33%)

Wells Fargo analyst Mohit…

Wells Fargo analyst Mohit Bansal initiated coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and $270 price target. He sees AbbVie's (ABBV) data in Cystic Fibrosis in Q1 of 2022 as a "mere overhang and not a meaningful threat," Bansal said. He sees the stock moving up $40-$60 per share if the competitor's combo data fails to impress and down to $20-$25 per share if the sweat chloride reduction is about 50 mmol/L or greater. The company's pipeline underappreciated, added Bansal.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$206.61 /

+1.28 (+0.62%)

ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

VRTX Vertex Pharmaceuticals
$206.61 /

+1.28 (+0.62%)

12/02/21 RBC Capital
Vertex Pharmaceuticals price target raised to $265 from $250 at RBC Capital
12/01/21 Stifel
Vertex Pharmaceuticals APOL1 clinical data looks strong, says Stifel
12/01/21 Piper Sandler
Vertex Phase 2 data an 'incremental positive,' says Piper Sandler
11/18/21 BMO Capital
Vertex Pharmaceuticals initiated with a Market Perform at BMO Capital
ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

12/08/21 Wells Fargo
AbbVie initiated with an Overweight at Wells Fargo
12/06/21 JPMorgan
AbbVie's label update for Rinvoq offered 'no surprises,' says JPMorgan
11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
VRTX Vertex Pharmaceuticals
$206.61 /

+1.28 (+0.62%)

ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

VRTX Vertex Pharmaceuticals
$206.61 /

+1.28 (+0.62%)

ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

VRTX Vertex Pharmaceuticals
$206.61 /

+1.28 (+0.62%)

ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

Initiation
AbbVie initiated with an Overweight at Wells Fargo » 16:22
12/08/21
12/08
16:22
12/08/21
16:22
ABBV

AbbVie

$121.88 /

+0.395 (+0.33%)

Wells Fargo analyst Mohit…

Wells Fargo analyst Mohit Bansal initiated coverage of AbbVie (ABBV) with an Overweight rating and $165 price target. Given how much Humira "overshadows the rest of the business," he argues that the "ex-Humira" business is underappreciated, Bansal tells investors. The business outside of Humira is growing at 10% revenue and 20% EPS CAGR, and is already 30% bigger than Eli Lilly (LLY), but is trading at a greater than 50% discount to Lilly, the analyst added.

ShowHide Related Items >><<
ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

12/06/21 JPMorgan
AbbVie's label update for Rinvoq offered 'no surprises,' says JPMorgan
11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/23/21 Societe Generale
AbbVie upgraded to Buy from Hold at Societe Generale
ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

ABBV AbbVie
$121.88 /

+0.395 (+0.33%)

Hot Stocks
New York AG announces $200M opioid settlement with Allergan » 11:35
12/08/21
12/08
11:35
12/08/21
11:35
ABBV

AbbVie

$121.10 /

-0.38 (-0.31%)

New York Attorney General…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABBV AbbVie
$121.10 /

-0.38 (-0.31%)

ABBV AbbVie
$121.10 /

-0.38 (-0.31%)

12/06/21 JPMorgan
AbbVie's label update for Rinvoq offered 'no surprises,' says JPMorgan
11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/23/21 Societe Generale
AbbVie upgraded to Buy from Hold at Societe Generale
ABBV AbbVie
$121.10 /

-0.38 (-0.31%)

ABBV AbbVie
$121.10 /

-0.38 (-0.31%)

ABBV AbbVie
$121.10 /

-0.38 (-0.31%)

ABBV AbbVie
$121.10 /

-0.38 (-0.31%)

Monday
Recommendations
AbbVie's label update for Rinvoq offered 'no surprises,' says JPMorgan » 15:07
12/06/21
12/06
15:07
12/06/21
15:07
ABBV

AbbVie

$121.57 /

+2.68 (+2.25%)

After AbbVie announced on…

After AbbVie announced on Friday that updated U.S. prescribing information for Rinvoq for the treatment of adults with moderate to severe rheumatoid arthritis, or RA, will now include additional information about risks as part of a class-wide update made by the FDA and that Rinvoq is now indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers, JPMorgan analyst Chris Schott said the updated label featured "no surprises" and noted that the new label is very much in-line with his expectations and FDA commentary from August. He believes the overall impact from the update will be "fairly manageable" and points to Rinvoq's pending indication expansion, most notably in atopic dermatitis, as an "important near-term catalyst" for AbbVie, on which he keeps an Overweight rating and $140 price target.

ShowHide Related Items >><<
ABBV AbbVie
$121.57 /

+2.68 (+2.25%)

ABBV AbbVie
$121.57 /

+2.68 (+2.25%)

11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/23/21 Societe Generale
AbbVie upgraded to Buy from Hold at Societe Generale
11/18/21 Piper Sandler
Vertex downgraded to Neutral at Piper ahead of AbbVie CF data
ABBV AbbVie
$121.57 /

+2.68 (+2.25%)

ABBV AbbVie
$121.57 /

+2.68 (+2.25%)

ABBV AbbVie
$121.57 /

+2.68 (+2.25%)

ABBV AbbVie
$121.57 /

+2.68 (+2.25%)

Options
Unusually active option classes on open December 6th » 09:40
12/06/21
12/06
09:40
12/06/21
09:40
WE

WeWork

$7.67 /

+0.01 (+0.13%)

, KRE

SPDR S&P Regional Banking ETF

$69.28 /

-0.025 (-0.04%)

, ARDX

Ardelyx

$1.50 /

-0.005 (-0.33%)

, DOCU

DocuSign

$135.03 /

+ (+0.00%)

, PDD

Pinduoduo

$54.42 /

+0.05 (+0.09%)

, RKLB

Rocket Lab

$13.00 /

+ (+0.00%)

, NCLH

Norwegian Cruise Line

$18.29 /

+ (+0.00%)

, CHWY

Chewy

$62.69 /

+ (+0.00%)

, ABBV

AbbVie

$118.84 /

-0.05 (-0.04%)

Unusual total active…

Unusual total active option classes on open include: WeWork (WE), SPDR S&P Regional Banking (KRE), Ardelyx (ARDX), DocuSign (DOCU), Pinduoduo (PDD), Rocket Lab USA (RKLB), Global X Uranium (URA), Norwegian Cruise Line (NCLH), Chewy (CHWY), and AbbVie (ABBV).

ShowHide Related Items >><<
WE WeWork
$7.67 /

+0.01 (+0.13%)

RKLB Rocket Lab
$13.00 /

+ (+0.00%)

PDD Pinduoduo
$54.42 /

+0.05 (+0.09%)

NCLH Norwegian Cruise Line
$18.29 /

+ (+0.00%)

DOCU DocuSign
$135.03 /

+ (+0.00%)

CHWY Chewy
$62.69 /

+ (+0.00%)

ARDX Ardelyx
$1.50 /

-0.005 (-0.33%)

ABBV AbbVie
$118.84 /

-0.05 (-0.04%)

WE WeWork
$7.67 /

+0.01 (+0.13%)

KRE SPDR S&P Regional Banking ETF
$69.28 /

-0.025 (-0.04%)

ARDX Ardelyx
$1.50 /

-0.005 (-0.33%)

12/01/21 Ladenburg
Ardelyx upgraded to Buy at Ladenburg on IBS-C treatment launch plan
12/01/21 Ladenburg
Ardelyx upgraded to Buy from Neutral at Ladenburg
12/01/21 Citi
Ardelyx price target raised to $13 from $7 at Citi
11/30/21 Citi
Ardelyx price target raised to $13 from $7 at Citi
DOCU DocuSign
$135.03 /

+ (+0.00%)

12/06/21 Wolfe Research
DocuSign downgraded to Peer Perform from Outperform at Wolfe Research
12/03/21
Fly Intel: Top five analyst downgrades
12/03/21 Oppenheimer
DocuSign now 'show me stock' after 'soft' Q3, says Oppenheimer
12/03/21 RBC Capital
DocuSign price target lowered to $220 from $345 at RBC Capital
PDD Pinduoduo
$54.42 /

+0.05 (+0.09%)

11/29/21
Fly Intel: Top five analyst downgrades
11/29/21 Citi
Pinduoduo downgraded to Neutral from Buy at Citi
11/02/21 Barclays
Pinduoduo initiated with Equal Weight, $103 target at Barclays
11/02/21 Barclays
Pinduoduo initiated with an Equal Weight at Barclays
RKLB Rocket Lab
$13.00 /

+ (+0.00%)

12/02/21 Stifel
Rocket Lab's Neutron rocket positions company for TAM expansion, says Stifel
11/30/21 BofA
Rocket Lab initiated with a Buy at BofA
11/30/21 BofA
Rocket Lab initiated with a Buy at BofA
10/04/21 BofA
Astra initiated with an Underperform at BofA
NCLH Norwegian Cruise Line
$18.29 /

+ (+0.00%)

11/16/21 Stifel
Norwegian Cruise Line weakness a buying opportunity, says Stifel
11/11/21 Berenberg
Norwegian Cruise Line price target raised to $27 from $25 at Berenberg
11/05/21 Deutsche Bank
Norwegian Cruise Line price target raised to $28 from $26 at Deutsche Bank
11/04/21 Wedbush
Norwegian Cruise Line price target raised to $35 from $30 at Wedbush
CHWY Chewy
$62.69 /

+ (+0.00%)

12/06/21 Wedbush
Chewy cut to Neutral at Wedbush, sees growth below consensus in 2022
12/06/21 Wedbush
Chewy downgraded to Neutral from Outperform at Wedbush
09/28/21
Fly Intel: Top five analyst upgrades
09/28/21 Wolfe Research
Wolfe upgrades Chewy to Outperform with 'plenty of strong growth ahead'
ABBV AbbVie
$118.84 /

-0.05 (-0.04%)

11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/23/21 Societe Generale
AbbVie upgraded to Buy from Hold at Societe Generale
11/18/21 Piper Sandler
Vertex downgraded to Neutral at Piper ahead of AbbVie CF data
RKLB Rocket Lab
$13.00 /

+ (+0.00%)

PDD Pinduoduo
$54.42 /

+0.05 (+0.09%)

NCLH Norwegian Cruise Line
$18.29 /

+ (+0.00%)

DOCU DocuSign
$135.03 /

+ (+0.00%)

CHWY Chewy
$62.69 /

+ (+0.00%)

ARDX Ardelyx
$1.50 /

-0.005 (-0.33%)

ABBV AbbVie
$118.84 /

-0.05 (-0.04%)

  • 13
    Apr
  • 20
    Apr
  • 05
    Mar
RKLB Rocket Lab
$13.00 /

+ (+0.00%)

PDD Pinduoduo
$54.42 /

+0.05 (+0.09%)

NCLH Norwegian Cruise Line
$18.29 /

+ (+0.00%)

DOCU DocuSign
$135.03 /

+ (+0.00%)

CHWY Chewy
$62.69 /

+ (+0.00%)

ABBV AbbVie
$118.84 /

-0.05 (-0.04%)

WE WeWork
$7.67 /

+0.01 (+0.13%)

RKLB Rocket Lab
$13.00 /

+ (+0.00%)

PDD Pinduoduo
$54.42 /

+0.05 (+0.09%)

NCLH Norwegian Cruise Line
$18.29 /

+ (+0.00%)

DOCU DocuSign
$135.03 /

+ (+0.00%)

CHWY Chewy
$62.69 /

+ (+0.00%)

ARDX Ardelyx
$1.50 /

-0.005 (-0.33%)

ABBV AbbVie
$118.84 /

-0.05 (-0.04%)

WE WeWork
$7.67 /

+0.01 (+0.13%)

RKLB Rocket Lab
$13.00 /

+ (+0.00%)

PDD Pinduoduo
$54.42 /

+0.05 (+0.09%)

NCLH Norwegian Cruise Line
$18.29 /

+ (+0.00%)

DOCU DocuSign
$135.03 /

+ (+0.00%)

CHWY Chewy
$62.69 /

+ (+0.00%)

ARDX Ardelyx
$1.50 /

-0.005 (-0.33%)

ABBV AbbVie
$118.84 /

-0.05 (-0.04%)

KRE SPDR S&P Regional Banking ETF
$69.28 /

-0.025 (-0.04%)

Hot Stocks
AbbVie: Upadacitinib achieved primary, key secondary endpoints in Phase 3 trial » 08:32
12/06/21
12/06
08:32
12/06/21
08:32
ABBV

AbbVie

$118.84 /

+1.99 (+1.70%)

AbbVie announced positive…

AbbVie announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib achieved both primary endpoints of clinical remission and endoscopic response at week 12. The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60% having previously failed two or more biologics. U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease. "The data from this first Phase 3 induction study in Crohn's disease suggest upadacitinib may help address the needs of patients suffering from this disease, as demonstrated in stringent endpoints such as endoscopic response," said Michael Severino, M.D., vice chairman and president, AbbVie. "We continue to leverage our expertise in IBD by driving research and development that help shape the IBD landscape and elevate standards of care for patients."

ShowHide Related Items >><<
ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/23/21 Societe Generale
AbbVie upgraded to Buy from Hold at Societe Generale
11/18/21 Piper Sandler
Vertex downgraded to Neutral at Piper ahead of AbbVie CF data
ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

Conference/Events
AbbVie management to meet virtually with Mizuho » 04:55
12/06/21
12/06
04:55
12/06/21
04:55
ABBV

AbbVie

$118.84 /

+1.99 (+1.70%)

Virtual Meeting to be…

Virtual Meeting to be held on December 6 hosted by Mizuho.

ShowHide Related Items >><<
ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/23/21 Societe Generale
AbbVie upgraded to Buy from Hold at Societe Generale
11/18/21 Piper Sandler
Vertex downgraded to Neutral at Piper ahead of AbbVie CF data
ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

Friday
Hot Stocks
AbbVie provides update to Rinvoq medication guide » 16:18
12/03/21
12/03
16:18
12/03/21
16:18
ABBV

AbbVie

$118.84 /

+1.99 (+1.70%)

AbbVie announced an…

AbbVie announced an update to the U.S. Prescribing Information and Medication Guide for Rinvoq for the treatment of adults with moderate to severe rheumatoid arthritis, or RA. This update follows a Drug Safety Communication, or DSC, issued on September 1 by the FDA following its final review of the post-marketing study, ORAL Surveillance, evaluating Xeljanz in patients with RA. The results of this study showed a higher rate of major adverse cardiac events, or MACE, malignancy, mortality and thrombosis in Xeljanz versus TNF blockers.1 The DSC and this label update apply to the class of systemically administered FDA-approved JAKs indicated for the treatment of RA and other inflammatory diseases. Based on this class-wide update, the U.S. label for Rinvoq will now include additional information about the risks of malignancy and thrombosis, and the addition of mortality and MACE risks within the Boxed Warnings and Warnings and Precautions sections. The indication has also been updated to the following: Rinvoq is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.

ShowHide Related Items >><<
ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

11/24/21 Truist
AbbVie price target raised to $135 from $118 at Truist
11/23/21 Societe Generale
Societe Generale upgrades AbbVie to Buy on better than anticipated execution
11/23/21 Societe Generale
AbbVie upgraded to Buy from Hold at Societe Generale
11/18/21 Piper Sandler
Vertex downgraded to Neutral at Piper ahead of AbbVie CF data
ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

ABBV AbbVie
$118.84 /

+1.99 (+1.70%)

Over a week ago
Recommendations
Vertex Pharmaceuticals price target raised to $265 from $250 at RBC Capital » 08:12
12/02/21
12/02
08:12
12/02/21
08:12
VRTX

Vertex Pharmaceuticals

$204.99 /

+18 (+9.63%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams raised the firm's price target on Vertex Pharmaceuticals to $265 from $250 and keeps an Outperform rating on the shares. The analyst is updating his model to reflect more de-risked prospects for the company's VX-147 kidney program following its data release yesterday. Abrahams adds that while Vertex shares saw some upside on the news, the stock still "does not nearly reflect" the fundamental fair value of the company's CF franchise and pipeline.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$204.99 /

+18 (+9.63%)

VRTX Vertex Pharmaceuticals
$204.99 /

+18 (+9.63%)

12/01/21 Stifel
Vertex Pharmaceuticals APOL1 clinical data looks strong, says Stifel
12/01/21 Piper Sandler
Vertex Phase 2 data an 'incremental positive,' says Piper Sandler
11/18/21 BMO Capital
Vertex Pharmaceuticals initiated with a Market Perform at BMO Capital
11/18/21 Piper Sandler
Vertex downgraded to Neutral at Piper ahead of AbbVie CF data
VRTX Vertex Pharmaceuticals
$204.99 /

+18 (+9.63%)

VRTX Vertex Pharmaceuticals
$204.99 /

+18 (+9.63%)

VRTX Vertex Pharmaceuticals
$204.99 /

+18 (+9.63%)

Recommendations
Vertex Pharmaceuticals APOL1 clinical data looks strong, says Stifel » 13:58
12/01/21
12/01
13:58
12/01/21
13:58
VRTX

Vertex Pharmaceuticals

/

+

Stifel analyst Paul…

Stifel analyst Paul Matteis believes Vertex Pharmaceuticals' APOL1 clinical data on Wednesday looks strong, with a 48% reduction in proteinuria. The company plans to advance the program and this is validating for Vertex Pharmaceuticals' ability to innovate outside of cystic fibrosis, the analyst contends. That said, Matteis notes that the baseline proteinuria level in this study was much lower than he expected and he still thinks there's an "open question here regarding the size of the market opportunity," and whether it is needle moving to the valuation as the cystic fibrosis franchise approaches $9B-$10B. He has a Hold rating on the shares.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
/

+

VRTX Vertex Pharmaceuticals
/

+

12/01/21 Piper Sandler
Vertex Phase 2 data an 'incremental positive,' says Piper Sandler
11/18/21 BMO Capital
Vertex Pharmaceuticals initiated with a Market Perform at BMO Capital
11/18/21 Piper Sandler
Vertex downgraded to Neutral at Piper ahead of AbbVie CF data
11/18/21 Piper Sandler
Vertex Pharmaceuticals downgraded to Neutral from Overweight at Piper Sandler
VRTX Vertex Pharmaceuticals
/

+

VRTX Vertex Pharmaceuticals
/

+

VRTX Vertex Pharmaceuticals
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.